• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    /C O R R E C T I O N -- Nootropics Depot/

    1/28/26 6:30:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HALO alert in real time by email

    In the news release, Nootropics Depot Sets Market Record With Highest Potency Saffron Extract, issued 16-Sep-2025 by Nootropics Depot over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:

    Nootropics Depot Sets Market Record With Highest Potency Saffron Extract

    TEMPE, Ariz., Sept. 16, 2025 /PRNewswire/ -- Nootropics Depot has announced the results of independent market testing, revealing that its High Potency Saffron Extract capsules deliver the highest concentrations of crocins and safranals of any saffron supplement currently available. Each capsule is standardized to 7.5% crocins and 1% safranals—levels that more than double those offered by leading competitors—affirming the product's market leadership for bioactive content.

    Nootropics Depot's High Potency Saffron contains the highest measured levels of crocins and safranals per capsule, delivering 1.97x more crocins and 1.18x more safranal  than any competing brand, based on third-party market testing. (PRNewsfoto/Nootropics Depot)

    The saffron extract is responsibly sourced from sustainable farms in Spain and crafted with a commitment to both quality and transparency. Every batch is subjected to rigorous in-house and third-party laboratory testing, ensuring that listed potencies are verified by ISO-accredited labs using advanced HPLC analysis. Nootropics Depot's data demonstrates that its saffron offers 1.97 times more crocins and 1.18 times more safranal per capsule than the next closest competitor tested.

    "Our customers deserve absolute confidence in the supplements they choose," said Paul Eftang, CEO of Nootropics Depot. "That's why we hold every batch to the highest analytical standards, make our results publicly available, and ensure that our High Potency Saffron delivers precisely what clinical research expects. We want people to see exactly what they're getting—backed by transparency, validated science, and world-class quality control."

    The extract is manufactured in cGMP-certified and FDA-registered facilities in Arizona, demonstrating the company's dedication to rigorous quality and safety standards set for dietary supplements. This commitment is evident in a robust standardization process that verifies the levels of key saffron bioactives, including crocins and safranals, in every batch. The result is a highly concentrated saffron supplement produced for customers seeking verified quality, transparency, and consistency in their wellness products.

    Nootropics Depot is a leading supplement company setting benchmark standards for quality and transparency in the industry. Founded in 2013, Nootropics Depot's mission has been to educate consumers on the science behind dietary supplements, and to advance the lab testing and quality control standards of the industry. Their stance is that consumers should be able to trust the products they buy, and that the brands selling those products have a duty to ensure they are using modern validated science. Nootropics Depot offers a wide range of high-quality cognitive enhancement and general health supplements. The company's commitment to quality and transparency is evident in their rigorous testing procedures, easily accessible Certificates of Analysis (COAs), and lab testing results available on every product page. In addition, they have formed a Scientific Advisory Board with board certified doctors, PhD researchers, and botanists to ensure that consumers can trust that scientific rigor is being upheld in everything they do. Nootropics Depot's newly redesigned website features a user-friendly interface, and includes an innovative quiz to help beginners find the right supplements for their needs. With partnerships with third-party labs, and collaboration with the Future Nutra Foundation, Nootropics Depot continues to push the boundaries of supplement quality and consumer education. For more information about Nootropics Depot's products and their commitment to transparency, visit nootropicsdepot.com.

    Media Contact

    Michael Packman

    Marketing Manager

    Nootropics Depot

    [email protected]

    Correction: The embedded table and the last sentence of the 2nd paragraph have been updated for accuracy.  

    Nootropics Depot is a leading supplement company setting benchmark standards for quality and transparency in the industry. Founded with a mission to empower consumers with knowledge about what they put into their bodies, Nootropics Depot offers a wide range of high-quality cognitive enhancement and general health supplements. (PRNewsfoto/Nootropics Depot)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nootropics-depot-sets-market-record-with-highest-potency-saffron-extract-302556716.html

    SOURCE Nootropics Depot

    Get the next $HALO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HALO

    DatePrice TargetRatingAnalyst
    12/4/2025$56.00Neutral → Sell
    Goldman
    10/14/2025$70.00Underperform → Market Perform
    Leerink Partners
    8/6/2025$75.00Equal-Weight → Overweight
    Morgan Stanley
    7/10/2025$55.00Neutral
    Goldman
    5/14/2025$62.00Overweight → Equal-Weight
    Morgan Stanley
    5/13/2025$47.00Market Perform → Underperform
    Leerink Partners
    10/7/2024$58.00 → $62.00Overweight → Equal Weight
    Wells Fargo
    9/19/2024$52.00 → $57.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $HALO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by SVP, CHIEF OPERATING OFFICER Caudill Cortney

    4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

    2/11/26 9:21:33 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by SVP, CHIEF LEGAL OFFICER Snyder Mark Howard

    4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

    2/11/26 9:20:59 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by SVP, CHIEF FINANCIAL OFFICER Labrosse Nicole

    4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

    2/11/26 9:20:34 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    SEC Filings

    View All

    $HALO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $HALO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Halozyme Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

    1/28/26 6:40:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

    12/9/25 4:45:01 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

    12/8/25 5:20:13 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    /C O R R E C T I O N -- Nootropics Depot/

    In the news release, Nootropics Depot Sets Market Record With Highest Potency Saffron Extract, issued 16-Sep-2025 by Nootropics Depot over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Nootropics Depot Sets Market Record With Highest Potency Saffron Extract TEMPE, Ariz., Sept. 16, 2025 /PRNewswire/ -- Nootropics Depot has announced the results of independent market testing, revealing that its High Potency Saffron Extract capsules deliver the highest concentrations of crocins and safranals of any saffron supplement currently available. Each capsule is standardized to 7.5% crocins and 1% s

    1/28/26 6:30:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

    SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, following the close of trading. Halozyme will host a conference call on Tuesday, February 17, 2026 at 1:30pm PT/4:30pm ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/analyst/624893800?pwd=q3lpEa6F A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a bioph

    2/10/26 4:05:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

    Updates Preliminary Unaudited 2025 Estimates:- Total Revenue of $1,385 - $1,400 million, YoY Growth of 36% to 38%1- Royalty Revenue of $865 - $870 million, YoY Growth of 51% to 52%1 Raises 2026 Financial Guidance Ranges: - Increases Total Revenue to $1,710 - $1,810 million, YoY Growth of 23% to 30%2 - Increases Royalty Revenue to $1,130 - $1,170 million, YoY Growth of 30% to 35%2 - Increases Adjusted EBITDA to $1,125 - $1,205 million3,4- Increases non-GAAP Diluted EPS to $7.75 - $8.253,4 Expands Drug Delivery Opportunity with Acquisition of Surf Bio and its Hyperconcentration Technology Conference Call Scheduled Today at 5:30am PT/8:30am ET SAN DIEGO, Jan. 28, 2026 /PRNewswire/ -- Halozyme T

    1/28/26 6:30:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics downgraded by Goldman with a new price target

    Goldman downgraded Halozyme Therapeutics from Neutral to Sell and set a new price target of $56.00

    12/4/25 8:27:01 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Halozyme Therapeutics from Underperform to Market Perform and set a new price target of $70.00

    10/14/25 1:19:46 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Halozyme Therapeutics from Equal-Weight to Overweight and set a new price target of $75.00

    8/6/25 7:53:02 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    Financials

    Live finance-specific insights

    View All

    Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

    SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, following the close of trading. Halozyme will host a conference call on Tuesday, February 17, 2026 at 1:30pm PT/4:30pm ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/analyst/624893800?pwd=q3lpEa6F A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a bioph

    2/10/26 4:05:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

    Updates Preliminary Unaudited 2025 Estimates:- Total Revenue of $1,385 - $1,400 million, YoY Growth of 36% to 38%1- Royalty Revenue of $865 - $870 million, YoY Growth of 51% to 52%1 Raises 2026 Financial Guidance Ranges: - Increases Total Revenue to $1,710 - $1,810 million, YoY Growth of 23% to 30%2 - Increases Royalty Revenue to $1,130 - $1,170 million, YoY Growth of 30% to 35%2 - Increases Adjusted EBITDA to $1,125 - $1,205 million3,4- Increases non-GAAP Diluted EPS to $7.75 - $8.253,4 Expands Drug Delivery Opportunity with Acquisition of Surf Bio and its Hyperconcentration Technology Conference Call Scheduled Today at 5:30am PT/8:30am ET SAN DIEGO, Jan. 28, 2026 /PRNewswire/ -- Halozyme T

    1/28/26 6:30:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

    SAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30 am PT / 8:30 am ET. On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2025 revenue results, updated 2026-2028 financial guidance and a business update. Pre-registration of the live call can be accessed via link here: https://registrations.events/direct/Q4I1205969. The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made ava

    1/20/26 4:05:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Halozyme Therapeutics Inc.

    SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

    11/12/24 9:36:57 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Halozyme Therapeutics Inc.

    SC 13G - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

    10/17/24 9:36:19 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Halozyme Therapeutics Inc. (Amendment)

    SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

    2/13/24 5:06:13 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HALO
    Leadership Updates

    Live Leadership Updates

    View All

    Jim Lang Elected to Halozyme's Board of Directors

    SAN DIEGO, Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 years of executive leadership experience in healthcare, life sciences, business services and data analytics. "Jim brings extensive experience in building and scaling innovative healthcare businesses, and we are delighted to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His strategic insight and proven ability to drive growth, including through M&A, will be a tremendous asset as we deliver on our growth strategy and create meaningful new value for our

    12/8/25 4:05:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

    KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

    9/4/24 8:00:00 AM ET
    $AVTX
    $DRRX
    $HALO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Medicinal Chemicals and Botanical Products

    Mahesh Krishnan Elected to Halozyme's Board of Directors

    SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. "Mahesh is a dynamic and highly accomplished healthcare executive, and we are pleased to welcome him to the Halozyme board," said Dr. Helen Torley, president and chief executive officer. "His experience with building and growing business opportunities in addition to his medical expertise, will provide valuable perspective as we expand our leadership as the premier provider of innovative drug delivery technologies." Dr.

    4/25/24 4:45:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care